Interstitial Cystitis
1996; Wiley; Volume: 3; Issue: 6 Linguagem: Inglês
10.1111/j.1442-2042.1996.tb00569.x
ISSN1442-2042
Autores Tópico(s)Urinary Tract Infections Management
ResumoInternational Journal of UrologyVolume 3, Issue 6 p. 415-420 Free Access Interstitial Cystitis C Lowell Parsons, Corresponding Author C Lowell Parsons Division of Urology, UCSD Medical Center, San Diego, California, USA*Division of Urology, UCSD Medical Center, 200 West Arbor Drive, San Diego, CA 92103–8897, USA.Search for more papers by this author C Lowell Parsons, Corresponding Author C Lowell Parsons Division of Urology, UCSD Medical Center, San Diego, California, USA*Division of Urology, UCSD Medical Center, 200 West Arbor Drive, San Diego, CA 92103–8897, USA.Search for more papers by this author First published: November 1996 https://doi.org/10.1111/j.1442-2042.1996.tb00569.xCitations: 10AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Oravisto KJ, Alfkhan OS, Jokinen EJ. Interstitial cystitis. Clinical and immunological findings. Scand J Urol Nephrol 1970; 4: 37– 42. 2 Hand JR. Interstitial cystitis, a report of 223 cases. J Urol 1949; 61: 291. 3 Hanash KA, Pool TL. Interstitial and hemorrhagic cystitis: viral, bacterial and fungal studies. J Urol 1970; 104: 705– 706. 4 Oravisto KJ, Alfthan OS. Treatment of interstitial cystitis with immunosuppression and chloroquine derivatives. Eur Urol 1976; 2: 82– 84. 5 Silk MR. Bladder antibodies in interstitial cystitis. J Urol 1970; 103: 307– 309. 6 Holm-Bentzen M., Lose G. Pathology and pathogenesis of interstitial cystitis. Urology 1987; 29(4 suppl): 8– 13. 7 Oravisto KJ. Interstitial cystitis as an autoimmune disease. A review. Eur Urol 1990; 6: 10– 13. 8 Weaver RG, Dougherty TF, Natoli C. Recent concepts of interstitial cystitis. J Urol 1963; 89: 377. 9 Lotz M., Villiger PM, Hugli T., Koziol J., Zuraw BL. Interleukin-6 and interstitial cystitis. J Urol 1994; 152: 869– 873. 10 Holm-Bentzen M., Jacobsen F., Nerstrom B., Lose G., Kristensen JK, Pedersen RH, Krarup T., Feggether J., Bates P., Barnard R., Larsen S., Hald T. Painful bladder disease: clinical and pathoanatomical differences in 115 patients. J Urol 1987; 138: 500. 11 Holm-Bentzen J., Halt T., Sondergaard I. Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid). J Urol 1986; 135: 187. 12 Kastrup J., Hand J., Larsen L. Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis. Br J Urol 1983; 55: 495– 500. 13 Sant GR. Interstitial cystitis: pathophysiology, clinical evaluation and treatment. Ann Urol 1989; 3: 172– 179. 14 Sant GR, Kalaru P., Ucci AA Jr. Mucosal mast cell (MMC) contribution to bladder mastocytosis in interstitial cystitis. J Urol 1988; 139: 276A. 15 Bjorling DE, Saban MR, Zine MJ, Haak-Frendscho M., Graziano FM, Saban R. In vitro passive sensitization of guinea pig, rhesus monkey and human bladders as a model of noninfectious cystitis. J Urol 1994; 152: 1603– 1608. 16 Saban R., Christensen M., Keith' I., Graziano FM, Undem BJ, Aagaard J., Bjorling DE, Bruskewitz RC. Experimental model for the study of bladder mast cell degradation and smooth muscle contraction. Sem Urol 1991; 9: 88– 101. 17 Eldrup J., Thorup J., Nielsen SL, Hald T., Hainau B. Permeability and ultrastructure of human bladder epithelium. Br J Urol 1983; 55: 488– 492. 18 Englund SE. Observation on the migration of some labeled substances between the urinary bladder and blood in rabbits. Acta Radiol 1956; 135(suppl): 9– 13. 19 Fellows GJ, Marshall DH. The permeability of human bladder epithelium to water and sodium. Invest Urol 1972; 9: 339– 344. 20 Hicks RM. The permeability of rat transitional epithelium. J Cell Biol 1966; 28: 21– 31. 21 Hicks RM, Ketterer B., Warren RC. The ultrastructure and chemistry of the luminal plasma membrane of the mammalian urinary bladder: a structure with low permeability to water and ions. Phil Trans R Soc Lond B 1974; 268: 23– 38. 22 Staehelin LA, Chlapowski FJ, Bonneville MA. Luminal plasma membrane of the urinary bladder. J Cell Biol 1972; 53: 73– 91. 23 Lewis SA, Diamond JM. Na+ transport by rabbit urinary bladder, a tight epithelium. J Membrane Biol 1976; 28: 1– 40. 24 Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in non-bacterial cystitis (interstitial cystitis). J Urol 1991; 145: 732– 735. 25 Lilly JD, Parsons CL. Bladder surface glycosaminoglycans: a human epithelial permeability barrier. Surg Gynecol Obstet 1990; 171: 493– 496. 26 Parsons CL, Boychuk D., Jones S., Hurst R., Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 1990; 143: 139– 142. 27 Parsons CL, Stauffer C., Schmidt J. Bladder surface glycosaminoglycans: an efficient mechanism of environmental adaptation. Science 1980; 208: 605– 607. 28 Parsons CL., Greenspan C., Mulholland SG. The primary antibacterial defense mechanism of the bladder. Invest Urol 1975; 13: 72– 76. 29 Parsons CL, Greenspan C., Moore SW, Mulholland SG. Role of surface mucin in primary antibacterial defense of bladder. Urology 1979; 9: 48– 52. 30 Gill WB, Jones KW, Ruggiero KJ. Protective effects of heparin and other sulfated glycosaminoglycans on crystal adhesion to urothelium. J Urol 1982; 127: 152– 154. 31 Hanno PM, Parsons CL, Shrom SH, Fritz R., Mulholland SG. The protective effect of heparin in experimental bladder infection. J Surg Res 1978; 25; 324– 329. 32 Parsons CL, Mulholland S., Anwar H. Antibactrial activity of bladder surface mucin duplicated by exogenous glycosaminoglycan (heparin). Infect Immun 1979; 24: 552– 557. 33 Grytc CC, Gregor HP. Poly-(styrene solfonic acid)-poly-(vinylidene fluoride) interpolymer ion-exchange membranes. J Polymer Sci 1976; 14: 1938. 34 Gregor HP. Anticoagulant activity of sulfonate polymers and copolymers. In: HP Gregor, (ed) Polymer science and technology. New York : Plenum Press, 1975; 5: 51– 56. 35 Gregor HP. Fixed charge ultrafiltration membranes. In: E. Selegny, (ed) Charged gels and membranes, part I. Holland : D Reider, 1976; 235. 36 Menter JM, Hurst RE, Nakamura N., West SS. Thermodynamics of mucopolysaccharide-dye binding. 111. Thermodynamic and cooperative parameters of acrid-ine orange-heparin system. Biopolymers 1979; 18: 493– 505. 37 Chelsky MJ, Rosen SI, Knight LC, Maurer AH, Hanno PM, Ruggieri MR. Bladder permeability in interstitial cystitis is similar to that of normal volunteers: direct measurement by transvesical absorption of 99m technetium-diethylenetriaminepentaacetic acid. J Urol 1994; 151: 346– 349. 38 Parsons CL, Mulholland S. Successful therapy of interstitial cystitis with pentosanpolysulfate. J Urol 1987; 138: 513– 516. 39 Mulholland SG, Hanno P., Parsons CL, Snat GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis: a double-blind placebo-controlled clinical study. Urology 1990; 35: 552– 558. 40 Fritjofsson A., Fall M., Juhlin R., Persson BE, Ruutu M. Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. J Urol 1987; 138: 508. 41 Holm-Bentzen M., Jacobsen F., Nerstrom B., Lose G., Kristensen JK, Pedersen RH, Krarup T., Feggetter J., Bates P., Barnard R., Larsen S., Hald T. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol 1987; 138: 503. 42 Parsons CL, Stein PC, Bidair M., Lebow D. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 1994; 13: 515– 520. 43 Hohlbrugger G., Lentsch P. Intravesical ions, osmolality and pH influence the volume pressure response in the normal rat bladder, and this is more pronounced after DMSO exposure. Eur Urol 1985; 11: 127– 130. 44 Parsons CL. Interstitial cystitis: clinical manifestations and diagnostic criteria in over 200 cases. Neurourol Urodyn 1990; 9: 241– 250. 45 Felsen D., Frye S., Trimble LA, Bavendam TG, Parsons CL, Sim Y., Vaughan Jr ED. Inflammatory mediator profile in urine and bladder wash fluid of patients with interstitial cystitis. J Urol 1994; 152: 355– 361. 46 Parsons CL, Parsons JK. Interstitial cystitis. In: S. Raz, (ed) Female urology. 2nd ed. Philadelphia : WB Saunders Company, 1996; 167– 182. 47 Holm-Bentzen M., Larsen S., Hainau B., Hald T. Non-obstructive detrusor myopathy in a, group of patients with chronic bacterial cystitis. Scand J Urol Nephrol 1985; 19: 21. 48 Hanno PM, Buehler J., Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J C'rol 1989; 141: 846– 848. 49 Stewart BH, Persky L., Kiser WS. The use of dimethylsulfoxide (DMSO) in the treatment of interstitial cystitis. J Urol 1968; 98: 671. 50 Theoharides T. Hydroxyzine in the treatment of interstitial cystitis. Urol Clin North Am 1994; 21: 113– 119. 51 Parsons CL, Housley T., Schmidt JD, LeBow D. Treatment of interstitial cystitis with intravesical heparin. Br JUrol 1994; 73: 504– 507. 52 Parsons CL, Benson G., Childs SJ, Hanno P., Sant GR, Webster G. A quantitatively controlled method to pro-spectively study interstitial cystitis and which demonstrates the efficacy of pentosanpolysulfate. J Urol 1993; 150: 845– 848. Citing Literature Volume3, Issue6November 1996Pages 415-420 ReferencesRelatedInformation
Referência(s)